CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 11, 2015--
WAVE Life Sciences Ltd. (NASDAQ: WVE), a preclinical biopharmaceutical
company using its proprietary chemistry platform to design, develop and
commercialize a broad pipeline of first-in-class or best-in-class
stereopure nucleic acid therapeutics candidates, today announced the
pricing of its initial public offering of 6,375,000 ordinary shares at a
price to the public of $16.00 per share. In addition, WAVE Life Sciences
has granted the underwriters a 30-day option to purchase up to an
additional 956,250 ordinary shares. The ordinary shares are expected to
begin trading on The NASDAQ Global Market on November 11, 2015 under the
This Smart News Release features multimedia. View the full release here:
Paul Bolno, President and CEO, WAVE Life Sciences (Photo: Business Wire).
Jefferies and Leerink Partners are acting as joint book-running managers
for the offering. JMP Securities and SunTrust Robinson Humphrey are
acting as co-managers for the offering.
The offering is being made only by means of a prospectus. When
available, copies of the final prospectus related to the offering may be
obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022,
telephone: (877) 547-6340, e-mail: Prospectus_Department@Jefferies.com;
or Leerink Partners LLC, Attention: Syndicate Department, One Federal
Street, 37th Floor, Boston, MA 02110, telephone: (800) 808-7525, ext.
6142, e-mail: email@example.com.
A registration statement relating to these securities has been filed
with the Securities and Exchange Commission and was declared effective
on November 10, 2015. This press release shall not constitute an offer
to sell or the solicitation of an offer to buy nor shall there be any
sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
View source version on businesswire.com: http://www.businesswire.com/news/home/20151111005369/en/
Source: WAVE Life Sciences Ltd.
Feinstein Kean Healthcare
Jessi Colund, 952-649-8600